Cibus (CBUS) Net Equity Issued and Repurchased (2021 - 2022)
Cibus (CBUS) posted Net Equity Issued and Repurchased of $329000.0 for Q4 2022, down 51.62% sequentially from $680000.0 in Q4 2021, and down 51.62% YoY from $680000.0 in Q4 2021.
Cibus (CBUS) Net Equity Issued and Repurchased (2021 - 2022) Analysis & Trends
Cibus has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $329000.0 in Q4 2022.
- Quarterly Net Equity Issued and Repurchased fell 51.62% year-over-year to $329000.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was $1.0 million (up 48.38% YoY) and the FY2022 annual result came in at $11.5 million, up 163.42% from the prior year.
- Net Equity Issued and Repurchased retreated to $329000.0 in Q4 2022 per CBUS's latest filing, from $680000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $680000.0 in Q4 2021 and troughed at $329000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 329,000.00 |
| Dec 31, 2022 | 329,000.00 |
| Dec 31, 2021 | 680,000.00 |
| Dec 31, 2021 | 680,000.00 |